ライフサイエンスコーパス: passive immunization

1 domain Abs have reinvigorated the concept of passive immunization.

2 to a more potent reagent for gene therapy or passive immunization.

3 protected mice from a lethal VV challenge by passive immunization.

4 ization, HSV-1 shedding, and latency through passive immunization.

5 T-helper cell subset 1 response and enables passive immunization.

6 mmunomodulatory effects as well as providing passive immunization.

7 antibodies for virus following active versus passive immunization.

8 transplantation can be reduced by aggressive passive immunization.

9 cued spatial reference memory deficits after passive immunization.

10 IgG-FcgammaR interactions during active and passive immunization.

11 otected against systemic GAS challenge after passive immunization.

12 apsule is a potential therapeutic target via passive immunization.

13 prevention of viral acquisition by active or passive immunization.

14 uction before initiating a 12 week course of passive immunization.

15 human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the preven

16 Unlike passive immunization, active immunization, which is the

17 Our data support a mechanism by which passive immunization acts centrally to stimulate microgl

18 Passive immunization against beta-amyloid (Abeta) has be

19 rides, an iron scavenging protein, isdB, and passive immunization against clumping factor A and lipot

20 We hypothesized that passive immunization against cryptosporidiosis could be

21 opes on defined antigens may provide optimal passive immunization against cryptosporidiosis.

22 Passive immunization against GPI reduced the number of i

23 utralizing antibodies that could be used for passive immunization against H5N1 virus or as guides for

24 sCD4-17b has potential utility for passive immunization against HIV-1 in several contexts,

25 n-sensitive P23 epitopes may have utility in passive immunization against murine C. parvum infection.

26 Therefore, we explored the effect of passive immunization against the CT of alpha-syn in the

27 Herein, we demonstrate that passive immunization against the Vbeta8-targeting SAg st

28 Passive immunization altered the growth and vascularizat

29 Ab has an important potential in therapeutic passive immunization and could help HIV-1 infected patie

30 he importance of the antibody format in oral passive immunization and encourage future expression of

31 such infection that may be prevented by oral passive immunization and might avert recurrent economic

32 app = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent chal

33 uorescence assays, growth inhibition assays, passive immunizations, and active immunizations indicate

34 However, traditional passive immunization approaches carry the risk of Fcgamm

35 fic antibodies, acquired by either active or passive immunization, are sufficient to protect against

36 We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombin

37 noculation all showed protective activity in passive immunization assays.

38 thermore, when MIP-2 was depleted in vivo by passive immunization, bleomycin-induced pulmonary fibros

39 Oral feed-based passive immunization can be a promising strategy to prol

40 Here we show that elements of active and passive immunization can be combined to create an effect

41 -CelTOS responses elicited by vaccination or passive immunization can inhibit sporozoite and ookinete

42 Our results suggest that passive immunization can reduce VAbeta levels, and modul

43 ed by active immunization or administered by passive immunization confer protection against S. aureus

44 us and vaccine-heterologous strains, whereas passive immunization confers only vaccine-homologous pro

45 To determine if passive immunization could decrease the incidence or sev

46 Thus, anti-gB passive immunization decreased fetal infection and intra

47 However, passive immunization did prevent mortality from pneumoni

48 mited the study's ability to address whether passive immunization diminishes perinatal transmission.

49 n, highlighting their utility for evaluating passive immunization efficacy.

50 serum is sufficient to confer protection, a passive immunization experiment using pooled nHgbA antis

51 In addition, passive immunization experiments demonstrated that antib

52 virus (ZEBOV) have been successfully used in passive immunization experiments in rodent models, but h

53 This was confirmed by passive immunization experiments in which the protective

54 al passive immunity in fish and fish-to-fish passive immunization experiments supports the concept of

55 In passive immunization experiments using challenge with wi

56 isms underlying host resistance, a series of passive immunization experiments were carried out using

57 To test this hypothesis, passive immunization experiments were carried out with n

58 om a lethal intranasal challenge with WU2 in passive-immunization experiments in which 10 mug of the

59 only a subset of G(C) MAbs protected mice in passive-immunization experiments, while some nonneutrali

60 ntibodies (mAbs) has re-ignited the field of passive immunization for HIV-1 prevention.

61 During studies of passive immunization for treatment of murine cryptococco

62 Passive immunization has been successfully employed for

63 soluble Abeta and tau levels after active or passive immunization in advanced aged 3xTg-AD mice that

64 omer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau

65 Using passive immunization in mice, the O:4-specific antibodie

66 Recommendations for using passive immunization in the general population or for th

67 l likely shape efforts to develop active and passive immunization interventions in response to the re

68 But most current strategies for passive immunization involve injection of antibodies for

69 As a result, passive immunization is an appropriate therapeutic optio

70 Consequently, passive immunization is being considered for treating Al

71 ocked TIGR4 adhesion in vitro and, following passive immunization, it protected mice against challeng

72 c antibodies in both the sera and lungs, and passive immunization led to the reduction of B. bronchis

73 a longer period of active immunotherapy, or passive immunization, may be required to provide suffici

74 enal disease is prevented in both active and passive immunization models by antigen-specific IgG1; ot

75 We have studied active and passive immunization models in mice to approach these is

76 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice.

77 Passive immunization of animals with a soluble TNF recep

78 Passive immunization of animals with anti-IL-12 serum i.

79 Passive immunization of B. burgdorferi-infected SCID mic

80 o the control normal mouse immunoglobulin G, passive immunization of BALB/c mice with MAb MoPn-23 res

81 Passive immunization of DENV-infected mice with polyclon

82 Passive immunization of hamsters with a mixture of toxin

83 In addition, passive immunization of mice demonstrated that antibody

84 n of rheumatoid arthritis (RA) by active and passive immunization of mice results in the development

85 Passive immunization of mice with a goat antiserum raise

86 Passive immunization of mice with anti-dPNAG-DT rabbit s

87 t, when performed during progression of HUS, passive immunization of mice with anti-Stx2 antibody pre

88 The passive immunization of mice with rabbit antimurine MCP-

89 Passive immunization of mice with rabbit antiserum confe

90 Active and passive immunization of mice with recombinant Arp or Arp

91 Passive immunization of mice with this MAb resulted in r

92 Passive immunization of murine models of Alzheimer disea

93 Passive immunization of naive, ablated mice with sera or

94 We used passive immunization of neonatal piglets (as a surrogate

95 Furthermore, passive immunization of NSCLC tumor-bearing mice with ne

96 ight be paired with antibiotic treatment for passive immunization of patients suffering from P. aerug

97 different HIV-1 isolates, and used this for passive immunization of pig-tailed macaques.

98 Passive immunization of pregnant women with primary HCMV

99 Passive immunization of rabbits with M131 administered i

100 Passive immunization of susceptible and resistant mouse

101 This report examines the effects of chronic, passive immunization on VAbeta and microhemorrhage in PD

102 l for prophylaxis against HIV-1 infection by passive immunization or gene therapy.

103 ns of ETA, may have therapeutic potential in passive immunization or topical treatment of burn patien

104 from nasopharyngeal infection; however, only passive immunization, or vaccination with inactive SpeA,

105 Abeta monoclonal antibody (mAb) effective in passive immunization paradigm.

106 red to controls (5.64; P = 0.0480), and both passive immunizations (PLY = 31.34% loss of retinal func

107 This compensating effect was blocked by passive immunization pretreatment with the monoclonal Ig

108 ions and to maximize antibody production and passive immunization protocols are being devised.

109 thers have demonstrated that both active and passive immunizations reduce Tau pathology and prevent c

110 We found that both active and passive immunization reduced corneal pathology scores af

111 se combinations might be sought in active or passive immunization regimes.

112 epithelial neutrophil activating protein by passive immunization significantly attenuated neutrophil

113 Moreover, active or passive immunization significantly reduced S. aureus col

114 Both active and passive immunization strategies against Staphylococcus a

115 nt, identification of immune correlates, and passive immunization strategies for pertussis.

116 Active and passive immunization strategies targeting the CPs protec

117 efore increase the potency and durability of passive immunization strategies to prevent HIV-1 infecti

118 s to date have focused on the development of passive immunization strategies to prevent or treat diss

119 een obtained with both probiotic therapy and passive immunization strategies.

120 timal FcgammaR interactions in the design of passive immunization strategies.

121 A passive immunization strategy for treating Ebola virus i

122 e of antibody preparations as a prophylactic passive immunization strategy in large populations.

123 c principles and scientific premises for the passive immunization strategy, including existing and em

124 Passive immunization studies are similarly hindered by t

125 Passive immunization studies demonstrated that productio

126 Both active and passive immunization studies have shown that antibodies

127 Previous passive immunization studies have suggested that the C-t

128 We addressed this issue in a series of passive immunization studies in Fischer 344 (F344) rats.

129 In addition, passive immunization studies showed that specific antibo

130 However, passive immunization studies suggested that protection r

131 Passive immunization studies, including a recent one by

132 In both active and passive immunization studies, Osp C (N40) antiserum fail

133 ccine design, our data have implications for passive-immunization studies in countries where clade C

134 The success of passive immunization suggests that immunoglobulin (Ig)-b

135 psular polysaccharide from A. baumannii as a passive immunization target.

136 Active or passive immunizations targeting Abeta are therefore of g

137 clinical studies demonstrate that active and passive immunizations targeting alpha-syn partially amel

138 ct against S. aureus infection of active and passive immunization that targeted 3 proteins involved i

139 One day after passive immunization, the animals were challenged i.p. w

140 (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies.

141 ely developed is immunotherapy-specifically, passive immunization through administration of exogenous

142 One approach is passive immunization through the administration of antib

143 and PG16-iMab, are promising candidates for passive immunization to prevent HIV-1 infection.

144 in the presence of maternal immunity or upon passive immunization to rabies virus with the pSG5rab.gp

145 Passive immunization using Abeta-specific antibodies has

146 n the absence of an effective HIV-1 vaccine, passive immunization using broadly neutralizing Abs or A

147 of FcRn-transported IgG was demonstrated by passive immunization using herpes simplex virus-2 (HSV-2

148 We have recently reported that passive immunization using monoclonal antibody M131 conv

149 Passive immunization using purified IgG from rabbits imm

150 tly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeu

151 In contrast to systemic passive immunization, we observed markedly reduced (>/=8

152 r, virus isolated from 1 mouse 3 weeks after passive immunization with 13.2 mg/kg antibody proved res

153 Passive immunization with 2B11 increased neutrophil infi

154 e protected against lethality by intravenous passive immunization with a CPB antibody prior to intrag

155 Passive immunization with a rabbit antiserum against dLO

156 als, no safety concerns were identified with passive immunization with a single bNAb (VRC01).

157 Passive immunization with Ab doses resulting in serum Ig

158 Passive immunization with Abs against whole C. parvum or

159 Active or passive immunization with alpha-toxin toxoid could prote

160 vent or treat AD, we compared the effects of passive immunization with an anti-Abeta42 mAb, an anti-A

161 laboratory has previously demonstrated that passive immunization with an anti-tau antibody, HJ8.5, d

162 Passive immunization with an antibody directed against t

163 Passive immunization with an antibody directed to an epi

164 e protected against lethality by intravenous passive immunization with an epsilon toxin antibody prio

165 ion with the amyloid beta (Abeta) protein or passive immunization with anti-Abeta antibodies has bene

166 protein transgenic mice have suggested that passive immunization with anti-Abeta antibodies may clea

167 Finally, the efficacy of passive immunization with anti-Abeta antibodies on the c

168 Passive immunization with anti-amyloid-beta peptide (Abe

169 Importantly, passive immunization with anti-Ftr1p immune sera protect

170 Lastly, passive immunization with anti-OmpA MAbs did not confer

171 Passive immunization with anti-Sse antiserum also signif

172 Passive immunization with anti-tau monoclonal antibodies

173 Passive immunization with antibodies against the envelop

174 Following passive immunization with antibody, no further adaptive

175 To evaluate the effect of passive immunization with anticapsular antibodies on nas

176 Passive immunization with antisera to these antigens is

177 Passive immunization with antiserum to CP5-CRM or CP8-CR

178 he disease are currently available, although passive immunization with C. parvum-specific antibodies

179 ly, studies in these same mice indicate that passive immunization with certain anti-Abeta antibodies

180 In primates, passive immunization with combinations containing human

181 Passive immunization with each antiserum significantly l

182 Passive immunization with either MAb 5C11 or 3E65 partia

183 Passive immunization with gammaDPGA mAbs protected >90%

184 Passive immunization with Guy's 13 prevents bacterial co

185 Passive immunization with hepatitis B surface antibody (

186 on and survival) was completely abrogated by passive immunization with high-titer human anti-MV antib

187 Passive immunization with Hla-specific antisera or activ

188 Anti-HIV passive immunization with human neutralizing monoclonal

189 We and others have previously shown that passive immunization with human nMAbs protected adult or

190 AIDS, the potential of pre- and postexposure passive immunization with hyperimmune serum to prevent o

191 llenging with the immunizing antigen, and by passive immunization with IgG or IgE anti-2,4,6-trinitro

192 Passive immunization with IgG1 and IgG2a mAb protected w

193 Passive immunization with immune (convalescent) serum co

194 roups of animals were given one prechallenge passive immunization with immune rabbit serum (IRS), M13

195 uire Ag in sensitized Ig-deficient mice, and passive immunization with immune serum or Ag-specific Ig

196 Passive immunization with MAb 3E65 was more effective in

197 Passive immunization with MAb 8E7 could significantly en

198 In wild-type mice, passive immunization with mAb against gp75 or active imm

199 Passive immunization with MAb MoPn-40 resulted in a lowe

200 Previously, we have demonstrated that passive immunization with monoclonal antibodies (MAbs) 4

201 Passive immunization with monoclonal antibodies (MAbs) s

202 Passive immunization with monoclonal antibodies (MAbs) t

203 (FnBPA) and fibronectin-binding protein B or passive immunization with monoclonal antibodies against

204 e to bind to the surface of M. tuberculosis, passive immunization with monoclonal antibodies directed

205 Passive immunization with monoclonal antibodies from hum

206 Passive immunization with monoclonal antibodies from hum

207 tion with recombinant PR (rPR) molecules and passive immunization with monoclonal antibodies reactive

208 tudies point out some potential drawbacks of passive immunization with monoclonal antibodies.

209 Passive immunization with monoclonal antibody TA99 targe

210 Challenge studies following passive immunization with neutralizing Abs suggest that

211 Passive immunization with neutralizing antibodies to IL-

212 pithelial neutrophil activating protein; (2) passive immunization with neutralizing antibodies to TNF

213 immunization with nontoxigenic Hla(H35L) or passive immunization with neutralizing monoclonal antibo

214 udy have implications for the improvement of passive immunization with polyclonal or monoclonal antib

215 Passive immunization with pooled sera from recombinant A

216 al challenge with P. yoelii sporozoites than passive immunization with purified IgG from rabbits immu

217 Passive immunization with rabbit antibodies against E. f

218 Active immunization with recombinant SasX or passive immunization with rabbit polyclonal anti-SasX Ig

219 ne mice challenged by transplantation and by passive immunization with sera from mice infected with e

220 amyloid peptide (Alphabeta) with vaccines or passive immunization with systemic monoclonal anti-Abeta

221 he aim of this study is to determine whether passive immunization with the 23-valent pneumococcal pol

222 Here we report that passive immunization with the broadly neutralizing antib

223 This study reports the effect of active or passive immunization with the conjugates or their antise

224 Passive immunization with the rabbit antisera resulted i

225 Importantly, passive immunization with the recombinant HBc-E2 particl

226 Our data indicate that passive immunization with this anti-Abeta monoclonal ant

227 Passive immunization with this antibody resulted in prot

228 Passive immunizations with antisera targeting outer memb